U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C14H19N3O.C6H8O7
Molecular Weight 437.4437
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OXOLAMINE CITRATE

SMILES

OC(=O)CC(O)(CC(O)=O)C(O)=O.CCN(CC)CCC1=NC(=NO1)C2=CC=CC=C2

InChI

InChIKey=RBZIGQJSMCOHSS-UHFFFAOYSA-N
InChI=1S/C14H19N3O.C6H8O7/c1-3-17(4-2)11-10-13-15-14(16-18-13)12-8-6-5-7-9-12;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-9H,3-4,10-11H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)

HIDE SMILES / InChI

Molecular Formula C6H8O7
Molecular Weight 192.1235
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C14H19N3O
Molecular Weight 245.3202
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Oxolamine under brand names Symphocal, Perebron is used in some countries as a cough suppressant for the treatment of pharyngitis, tracheitis, bronchitis, bronchiectasis, pertussis. Oxolamine possesses anti-inflammatory activity, which causes a reduction in the irritation of the nervous receptors of the respiratory tract.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Perebron

Approved Use

Unknown
Palliative
Perebron

Approved Use

Unknown
Palliative
Perebron

Approved Use

Unknown
Palliative
Perebron

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
15 mL single, oral
Overdose
Dose: 15 mL
Route: oral
Route: single
Dose: 15 mL
Sources:
unhealthy, CHILD
Health Status: unhealthy
Age Group: CHILD
Sex: M
Food Status: UNKNOWN
Sources:
Disc. AE: Visual hallucinations...
AEs leading to
discontinuation/dose reduction:
Visual hallucinations
Sources:
AEs

AEs

AESignificanceDosePopulation
Visual hallucinations Disc. AE
15 mL single, oral
Overdose
Dose: 15 mL
Route: oral
Route: single
Dose: 15 mL
Sources:
unhealthy, CHILD
Health Status: unhealthy
Age Group: CHILD
Sex: M
Food Status: UNKNOWN
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
inconclusive [IC50 6.3096 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
yes [IC50 5.0119 uM]
PubMed

PubMed

TitleDatePubMed
Effect of oxolamine on cough sensitivity in COPD patients.
2002 Jan
Effect of oxolamine on anticoagulant effect of warfarin.
2006 Jan 15
Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats.
2007 Apr
Patents

Sample Use Guides

In general, 15-25 mg per kilogram per day should be given by dividing four equal doses. In children over 2 years: 1-2 ml of 5 ml Adults: 2 ml of 5 ml 4 times daily 4 hours a day, after an equal amount of water.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 19:17:25 GMT 2025
Edited
by admin
on Mon Mar 31 19:17:25 GMT 2025
Record UNII
K5X4XBR694
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BREDON
Preferred Name English
OXOLAMINE CITRATE
MART.   MI   WHO-DD  
Systematic Name English
NSC-759304
Code English
5-(2-(DIETHYLAMINO)ETHYL)-3-PHENYL-1,2,4-OXADIAZOLE CITRATE (1:1)
Systematic Name English
OXOLAMINE CITRATE [MART.]
Common Name English
FLOGOBRON
Brand Name English
BRONCATAR
Brand Name English
PRILON
Brand Name English
PEREBRON
Brand Name English
SKF-9976
Code English
Oxolamine citrate [WHO-DD]
Common Name English
AF-438
Code English
SKF 9976
Code English
OXOLAMINE CITRATE [MI]
Common Name English
Code System Code Type Description
ECHA (EC/EINECS)
217-760-6
Created by admin on Mon Mar 31 19:17:25 GMT 2025 , Edited by admin on Mon Mar 31 19:17:25 GMT 2025
PRIMARY
CAS
1949-20-8
Created by admin on Mon Mar 31 19:17:25 GMT 2025 , Edited by admin on Mon Mar 31 19:17:25 GMT 2025
PRIMARY
NSC
759304
Created by admin on Mon Mar 31 19:17:25 GMT 2025 , Edited by admin on Mon Mar 31 19:17:25 GMT 2025
PRIMARY
PUBCHEM
16045
Created by admin on Mon Mar 31 19:17:25 GMT 2025 , Edited by admin on Mon Mar 31 19:17:25 GMT 2025
PRIMARY
EVMPD
SUB03576MIG
Created by admin on Mon Mar 31 19:17:25 GMT 2025 , Edited by admin on Mon Mar 31 19:17:25 GMT 2025
PRIMARY
EPA CompTox
DTXSID9045556
Created by admin on Mon Mar 31 19:17:25 GMT 2025 , Edited by admin on Mon Mar 31 19:17:25 GMT 2025
PRIMARY
FDA UNII
K5X4XBR694
Created by admin on Mon Mar 31 19:17:25 GMT 2025 , Edited by admin on Mon Mar 31 19:17:25 GMT 2025
PRIMARY
MERCK INDEX
m8313
Created by admin on Mon Mar 31 19:17:25 GMT 2025 , Edited by admin on Mon Mar 31 19:17:25 GMT 2025
PRIMARY Merck Index
RXCUI
59053
Created by admin on Mon Mar 31 19:17:25 GMT 2025 , Edited by admin on Mon Mar 31 19:17:25 GMT 2025
PRIMARY RxNorm
SMS_ID
100000085508
Created by admin on Mon Mar 31 19:17:25 GMT 2025 , Edited by admin on Mon Mar 31 19:17:25 GMT 2025
PRIMARY
MESH
C008735
Created by admin on Mon Mar 31 19:17:25 GMT 2025 , Edited by admin on Mon Mar 31 19:17:25 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY